What are the latest funding news in the femtech market? (April 2026)
Download our beautiful pitch about the femtech market
In our femtech market deck, you will find everything you need to understand the market
April 2026 delivered a steady flow of femtech funding, with capital flowing into everything from ovarian cancer diagnostics to portable fertility insurance.
The month's biggest story was Midi Health crossing unicorn status with a $100M Series D, but smaller pre-seed and seed rounds dominated the deal count.
Menopause, maternal health, and reproductive diagnostics emerged as the most active sub-segments in the femtech market.
And if you want to better understand this new industry, you can download our pitch covering the femtech market.
Insights
- Menopause care dominated the quarter in dollar volume, with Midi Health's $100M Series D and Coral's C$4M round signaling that insurers and investors are finally treating perimenopause as a billion-dollar clinical category rather than a wellness niche.
- Pre-seed and seed rounds made up roughly two-thirds of the 12 deals tracked, suggesting the femtech market is still in an early-formation phase where most capital is flowing to unproven concepts rather than late-stage scale-ups.
- Diagnostics startups attracted disproportionate attention, with Proseek Bio, Pregnolia, Feminai, and Xella Health all raising for female-specific tests spanning ovarian cancer, preterm birth, breast cancer, and multi-omic hormonal panels.
- Geographic diversity was striking: deals landed in Australia, Canada, Switzerland, Israel, India, the UK, and the US, confirming that femtech is no longer concentrated in a single North American hub.
- Fertility financing is emerging as its own sub-category, with Flora Fertility's $5M seed for portable fertility insurance pointing to growing demand for coverage that does not depend on employer benefits.
- AI was explicitly mentioned in at least four of the 12 deals (myStoria, Matresa, Pinky Promise, Feminai), reflecting how women's health founders are leaning on AI to scale clinical navigation and screening.
- Maternal health drew capital across the full pregnancy lifecycle, from Matresa's preventative prenatal platform to Pregnolia's preterm birth diagnostic to SimpliFed's postpartum and lactation expansion.
- The average disclosed round size sat around $11.6M, but the median was closer to $3.7M, showing how one late-stage deal (Midi) skews headline numbers in a market still dominated by small checks.
- Privacy-first consumer femtech made a notable return with 28x's £1.2M launch round, suggesting investor appetite for period-tracking products that do not monetize user data amid ongoing reproductive privacy concerns.
- India's Pinky Promise securing a $1M pre-seed highlights how femtech is expanding into emerging markets where gynecological care access remains a significant unmet need.
As this chart shows, and as featured in our femtech market deck, search interest in femtech has increased significantly
Summary table of the latest funding deals in the femtech market as of April 2026
We define the femtech market as technology-enabled products and services that address women's reproductive and other female-specific health needs.
We include solutions focused on menstrual and cycle health, fertility and contraception, pregnancy and postpartum, menopause, pelvic and sexual health, and clinically oriented tools for conditions that predominantly or uniquely affect women (e.g., breast and gynecological cancers).
We exclude general-purpose health, wellness, fitness, mental health, and consumer apps that are not specifically designed around women's biology, care pathways, or life stages.
You can also read our detailed analysis to understand how funding activity in the femtech market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the femtech market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Xella Health | January 12, 2026 | $3.7M | Pre-seed | Women's Diagnostics & Hormonal Health |
| Feminai | January 12, 2026 | $6M | Seed | Breast Cancer Screening |
| Pinky Promise | January 22, 2026 | $1M | Pre-seed | Digital Clinic & Gynecological Health |
| Midi Health | February 3, 2026 | $100M | Series D | Menopause Care |
| Matresa | February 18, 2026 | $0.4M | Pre-seed | Maternal Health |
| Pregnolia | March 3, 2026 | $4.4M | Financing | Pregnancy Diagnostics |
| 28x | March 4, 2026 | $1.5M | Seed | Menstrual & Cycle Health |
| myStoria | March 31, 2026 | $1.6M | Seed | Reproductive Health Navigation |
| Coral | April 1, 2026 | $2.9M | Acceleration Round | Menopause Care |
| SimpliFed | April 7, 2026 | $10.8M | Series A | Pregnancy & Postpartum Care |
| Flora Fertility | April 7, 2026 | $5M | Seed | Fertility Insurance & Financing |
| Proseek Bio | April 8, 2026 | $1M | Seed | Ovarian Cancer Diagnostics |
All the latest funding deals during in the femtech market as of April 2026
Proseek Bio raised A$1.5M in seed funding to commercialize its ovarian cancer detection blood test in early April 2026
When was it?
The Proseek Bio funding round was announced on April 8, 2026.
Who are they?
Proseek Bio is an Australian diagnostics startup building a blood test called OC-Triage that helps doctors decide which women with suspected ovarian cancer actually need diagnostic surgery.
Geographical focus?
Proseek Bio is regional, with an initial focus on Australia before broader international expansion.
Why do we include them in the femtech market?
Proseek Bio fits squarely within femtech as a clinically oriented gynecologic oncology diagnostic, targeting a cancer pathway that is specific to female biology.
What is the company stage?
Proseek Bio is at the clinical MVP stage, with a defined product and seed capital to push toward clinical lab deployment and validation.
How much did they raise?
Proseek Bio raised approximately $1M (A$1.5M) in this round.
What round is it?
This was a seed round for Proseek Bio.
Why did they raise?
Proseek Bio raised the capital to advance OC-Triage toward lab deployment, clinical validation, and eventual market entry and regulatory work.
Flora Fertility secured $5M in seed funding to expand its individually owned fertility insurance product in early April 2026
When was it?
The Flora Fertility funding round was announced on April 7, 2026.
Who are they?
Flora Fertility sells portable fertility insurance that individuals can keep across job changes, covering diagnostics, medications, IUI, and IVF.
Geographical focus?
Flora Fertility is regional, focused on the North American market.
Why do we include them in the femtech market?
Flora Fertility is a pure-play fertility financing and insurance product built specifically around women's fertility care pathways.
What is the company stage?
Flora Fertility is at early product-market fit, with a defined product and distribution partnerships following a prior pre-seed round.
How much did they raise?
Flora Fertility raised $5M in this round.
What round is it?
This was a seed round for Flora Fertility, led by ManchesterStory with participation from Slauson & Co., BDC, and existing investors.
Why did they raise?
Flora Fertility raised the capital to make fertility coverage portable outside employer-sponsored benefits and expand access through app and SMB partnerships.
This chart, included in our femtech market deck, compares the main business model options for menopause telehealth platforms
SimpliFed raised a $10.8M Series A to expand from virtual lactation support into virtual OB care in early April 2026
When was it?
The SimpliFed funding round was announced on April 7, 2026.
Who are they?
SimpliFed started with virtual lactation support and is now expanding into broader virtual obstetric care for prenatal and postpartum patients.
Geographical focus?
SimpliFed is regional, serving patients across the United States.
Why do we include them in the femtech market?
SimpliFed is a pure-play pregnancy and postpartum care delivery business built around maternal and infant feeding pathways.
What is the company stage?
SimpliFed is in growth stage, being in-network with major health plans and on track to serve 5% of U.S. births in 2026.
How much did they raise?
SimpliFed raised $10.8M in this round.
What round is it?
This was a Series A for SimpliFed, co-led by Morningside and Hesperia Capital with participation from Foreground Capital, AHA Social Impact Fund, and Elizabeth Street Ventures.
Why did they raise?
SimpliFed raised the capital to expand from lactation into broader virtual OB, grow its maternal health operating system, and deepen EMR interoperability.
Coral added C$4M in an acceleration round to scale its virtual menopause care platform in early April 2026
When was it?
The Coral funding round was announced on April 1, 2026.
Who are they?
Coral runs a virtual clinic for women in perimenopause and menopause, combining hormonal care, metabolic health, and weight management.
Geographical focus?
Coral is regional, focused on the Canadian market.
Why do we include them in the femtech market?
Coral is a direct menopause care platform fully centered on a women-specific life stage.
What is the company stage?
Coral is at early growth stage, having launched a year earlier with outcomes data supporting its integrated model.
How much did they raise?
Coral raised approximately $2.9M (C$4M) in this round.
What round is it?
This was an acceleration round for Coral, led collectively by Brightspark, Diagram, AQC Capital, Anges Quebec, and The51.
Why did they raise?
Coral raised the capital to scale its integrated menopause care model rather than symptom-by-symptom telehealth.
This chart, included in our femtech market deck, shows how Flo Health is capturing share in femtech
myStoria raised $1.625M in seed funding to build a reproductive health care coordination platform at the end of March 2026
When was it?
The myStoria funding round was announced on March 31, 2026.
Who are they?
myStoria is building an AI-plus-human reproductive health care coordination platform for infertility, PCOS, endometriosis, painful periods, and perimenopause.
Geographical focus?
myStoria is regional, starting in Canada with plans to expand.
Why do we include them in the femtech market?
myStoria is purpose-built around reproductive health navigation and care coordination, making it a clear fit for the femtech market.
What is the company stage?
myStoria is at MVP to early product-market fit stage, expanding from fertility navigation into broader reproductive health.
How much did they raise?
myStoria raised $1.625M in this round.
What round is it?
This was a seed round for myStoria, led by Graphite Ventures with participation from Conexus Venture Capital, Adrenaline Fund, and Phoenix Fire Fund.
Why did they raise?
myStoria raised the capital to broaden from fertility into full reproductive health coordination and reduce the administrative burden on patients.
28x launched with £1.2M in funding for its free, privacy-first period tracking app in early March 2026
When was it?
The 28x funding round was announced on March 4, 2026.
Who are they?
28x is a privacy-first period tracking and women's health app that runs entirely on-device instead of sending user data to cloud servers.
Geographical focus?
28x has a broad global consumer focus rather than a specific regional strategy.
Why do we include them in the femtech market?
28x sits cleanly in menstrual and cycle health, one of the core femtech categories.
What is the company stage?
28x is at MVP and early launch stage, having just released the product when the funding was announced.
How much did they raise?
28x raised approximately $1.5M (£1.2M) in this round.
What round is it?
This was effectively a launch or seed-style round for 28x, backed by the Philips Foundation and 40 philanthropic angel investors.
Why did they raise?
28x raised the capital to launch a free product built for the women who are underserved by subscription-heavy femtech apps.
In our femtech market deck, we identify pain points entrepreneurs should prioritize
Pregnolia secured $4.4M backed by the European Innovation Council to advance its preterm birth diagnostic in early March 2026
When was it?
The Pregnolia funding round was announced on March 3, 2026.
Who are they?
Pregnolia is developing a diagnostic device that measures cervical stiffness to predict preterm birth risk more accurately than existing methods.
Geographical focus?
Pregnolia is regional, based in Switzerland with a European market focus.
Why do we include them in the femtech market?
Pregnolia is a pregnancy and obstetric diagnostics company focused on a women-specific maternal care pathway.
What is the company stage?
Pregnolia is at clinical validation and pre-commercial stage, with published clinical evidence supporting the platform.
How much did they raise?
Pregnolia raised approximately $4.4M (CHF 3.4M) in this round.
What round is it?
This was a financing round rather than a classic venture series, with the European Innovation Council Accelerator as institutional lead.
Why did they raise?
Pregnolia raised the capital to advance its novel biomarker-based test for preterm birth risk and build on recently published clinical evidence.
Matresa raised £315K in pre-seed funding to build an AI-powered maternal health platform in February 2026
When was it?
The Matresa funding round was announced on February 18, 2026.
Who are they?
Matresa is building an AI-supported preventative maternal health platform for support and screening during pregnancy and early parenthood.
Geographical focus?
Matresa is regional, focused on the United Kingdom.
Why do we include them in the femtech market?
Matresa is a dedicated maternal health product rather than a general health app, placing it firmly in the femtech market.
What is the company stage?
Matresa is at idea to early MVP stage, with pre-seed funding and a platform still under development.
How much did they raise?
Matresa raised approximately $0.4M (£315K) in this round.
What round is it?
This was a pre-seed round for Matresa, led by SFC Capital.
Why did they raise?
Matresa raised the capital to move maternal care from reactive to preventative and support mothers, partners, and employers during maternity leave.
This market map, featured in our femtech market deck, highlights top companies and startups in the femtech market
Midi Health raised $100M in a Series D round and surpassed a $1 billion valuation in early February 2026
When was it?
The Midi Health funding round was announced on February 3, 2026.
Who are they?
Midi Health is an insurance-covered telehealth provider focused on perimenopause and menopause care.
Geographical focus?
Midi Health is regional, operating nationally across the United States.
Why do we include them in the femtech market?
Midi Health is a textbook menopause care delivery company, one of the most clearly defined femtech sub-categories.
What is the company stage?
Midi Health is at growth and scale-up stage, serving tens of thousands of patients weekly and now operating as a unicorn.
How much did they raise?
Midi Health raised $100M in this round at a valuation exceeding $1 billion.
What round is it?
This was a Series D for Midi Health, led by Goodwater Capital with new investors Foresite Capital and Serena Ventures joining existing backers.
Why did they raise?
Midi Health raised the capital to keep scaling menopause care nationally as patient demand and insurer coverage expand.
Pinky Promise raised $1M in pre-seed funding for its AI-enabled women's health platform in late January 2026
When was it?
The Pinky Promise funding round was announced on January 22, 2026.
Who are they?
Pinky Promise is an AI-enabled digital clinic for women's health covering menstrual problems, UTIs, fertility, pregnancy, and PCOS.
Geographical focus?
Pinky Promise is regional, focused on the Indian market.
Why do we include them in the femtech market?
Pinky Promise is organized around women's gynecological and reproductive care pathways, making it a clear digital clinic fit for femtech.
What is the company stage?
Pinky Promise is at early product-market fit, reporting hundreds of thousands of women served and around 40,000 paying customers.
How much did they raise?
Pinky Promise raised $1M in this round.
What round is it?
This was a pre-seed round for Pinky Promise, led by the Rebalance Angel Community with participation from Subramanian Ramadorai and Mala Ramadorai.
Why did they raise?
Pinky Promise raised the capital to expand care offerings, open physical clinics, and grow its supplements portfolio.
This chart, included in our femtech market deck, shows annual funding in femtech startups
Feminai raised $6M in seed funding for its AI-powered at-home breast cancer screening wearable in mid-January 2026
When was it?
The Feminai funding round was announced on January 12, 2026.
Who are they?
Feminai is developing a wearable breast cancer screening device that tracks breast density and blood-flow changes and uses AI to analyze the data.
Geographical focus?
Feminai is regional, based in Israel with plans for international expansion.
Why do we include them in the femtech market?
Feminai is a breast health screening wearable targeting a female-specific cancer pathway, a clear femtech category.
What is the company stage?
Feminai is at clinical MVP and early validation stage, having completed its first in-human trial but still working toward regulatory approval.
How much did they raise?
Feminai raised $6M in this round.
What round is it?
This was a seed round for Feminai, led by Vertex Ventures Israel with participation from ICI Fund, Fusion VC, Arben Ventures, and Cactus Capital.
Why did they raise?
Feminai raised the capital to build out the team, push through regulatory work, and prepare for go-to-market.
Xella Health raised $3.7M in pre-seed funding for multi-omic women's health testing in mid-January 2026
When was it?
The Xella Health funding round was announced on January 12, 2026.
Who are they?
Xella Health is building multi-omic women's health diagnostics using menstrual fluid plus blood to generate insights across fertility, hormonal health, perimenopause, and early cancer detection.
Geographical focus?
Xella Health is regional, focused on the United States market.
Why do we include them in the femtech market?
Xella Health is based directly on female-specific biology, particularly menstrual fluid, placing it squarely in women's diagnostics.
What is the company stage?
Xella Health is at MVP and pre-launch stage, planning a Spring 2026 launch with a waitlist in place.
How much did they raise?
Xella Health raised $3.7M in this round.
What round is it?
This was a pre-seed round for Xella Health, led by Precursor Ventures with participation from Capital F, Ulu Ventures, and angel investors.
Why did they raise?
Xella Health raised the capital to fund launch and build the diagnostic infrastructure needed to decode female biology at scale.
Related blog posts
- How strong is fundraising in the femtech market right now?
- The most recent news in the femtech market
- What is the true size of the femtech market?
- How funding activity has evolved in the femtech market
- What are the key fundraising trends in the femtech market?
- All the funding deals announced in the femtech market
- Which companies have raised the most funding in the femtech market?
- Which companies are the most valued in the femtech market?
